Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:46-56. doi: 10.1111/jdv.15313.
Melanoma is a life-threatening disease of the skin with an increasing incidence of approximately 87 000 new cases treated per year in the European Union and the European Free Trade Association states resulting in considerable costs for the society. Since the use of sunbeds is known to be a risk factor, which can be easily avoided, costs of malignant melanoma attributable to sunbed use are modelled in the present study.
Costs-of-illness of melanoma were calculated and compared for all member states of the European Union and the European Free Trade Association states using an established modelling approach. Calculations were based on a systematic literature research. For countries with no available information on cost-of-illness the gross domestic product, health expenditures and gross national income served as a basis for extrapolation of costs. International comparison was enabled by adjusting costs by the national purchasing power parity.
After adjusting melanoma treatment costs for the purchasing power parity, direct costs per patient vary between € 1056 in Romania and € 10 215 in Luxembourg. Costs due to morbidity range from € 102 per patient in Sweden and € 5178 in the UK resulting in total costs of € 1751-€ 12 611 per patient. Average weighted total costs per patient amount for € 6861-€ 6967 annually. In total, in 2012 approximately 4450 new cases of melanoma have been induced by sunbed use in the 31 included countries, which corresponds to 5.1% of all incident melanoma cases. National attributable melanoma costs range from € 1570 in Malta to € 11.1 million in Germany and sum up to an amount of € 32.5-€ 33.4 million for all countries.
This article provides a first estimation on costs of melanoma in Europe. It illustrates the contribution of exposure to artificial ultraviolet light in the economic burden of malignant melanoma.
黑色素瘤是一种危及生命的皮肤疾病，在欧盟和欧洲自由贸易联盟国家，每年约有 87000 例新病例接受治疗，给社会造成了相当大的成本。由于已知使用日光浴床是一个可以轻易避免的风险因素，因此本研究对归因于使用日光浴床的恶性黑色素瘤成本进行建模。
使用既定的建模方法，计算并比较了所有欧盟成员国和欧洲自由贸易联盟国家的黑色素瘤疾病成本。计算基于系统的文献研究。对于没有疾病成本信息的国家，国内生产总值、卫生支出和国民总收入作为成本外推的基础。通过根据国家购买力平价调整成本，实现了国际比较。
调整黑色素瘤治疗成本的购买力平价后，每位患者的直接成本在罗马尼亚的 1056 欧元和卢森堡的 10215 欧元之间。发病率导致的成本范围从瑞典的每位患者 102 欧元和英国的 5178 欧元不等，导致每位患者的总费用为 1751-12611 欧元。每位患者的平均加权总成本每年为 6861-6967 欧元。2012 年，在 31 个纳入国家中，约有 4450 例新的黑色素瘤病例归因于日光浴床使用，占所有新发病例的 5.1%。归因于黑色素瘤的国家成本从马耳他的 1570 欧元到德国的 1110 万欧元不等，所有国家的总成本为 3250-3340 万欧元。
本文首次对欧洲的黑色素瘤成本进行了估计。它说明了暴露于人工紫外线在恶性黑色素瘤的经济负担中的贡献。
